UCBJY (UCBJY) Stock Price & Analysis
UCBJY (UCBJY) rose 0.59% to USD 139.01 as of July 25, 2026 at 02:25 UTC, according to Nexqual real-time market data.
UCBJY last closed at USD 138.2; the session ranged USD 139.01–141.84 on volume of 3,768 shares. Market capitalization is $52.96B, with a 52-week range of USD 103.43–168.76 (PNK). Source: Nexqual, July 25, 2026 at 02:25 UTC.
Key Statistics (as of July 25, 2026 at 02:25 UTC)
| Price | USD 139.01 |
|---|---|
| Change | ▲ 0.59% (up) |
| Previous Close | USD 138.2 |
| Open | USD 141.82 |
| Day Range | USD 139.01 – 141.84 |
| 52-Week Range | USD 103.43 – 168.76 |
| Volume | 3,768 shares |
| Market Cap | $52.96B |
| Exchange | PNK |
Technical Analysis (UCBJY)
Nexqual's technical model rates UCBJY "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 02:25 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 44.96 (neutral) |
| vs SMA50 | Below (USD 143.4) |
| MACD | -2.18 (negative) |
Analyst Ratings (UCBJY)
Wall Street analysts rate UCBJY "Strong Buy" based on 2 analysts, with a mean price target of USD 161.97 (range USD 159.92–164.02), per Nexqual as of July 25, 2026 at 02:25 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 161.97 |
| High Target | USD 164.02 |
| Low Target | USD 159.92 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (UCBJY)
Source: Nexqual, July 25, 2026 at 02:25 UTC.
Financials & Fundamentals (UCBJY)
| Total Revenue | $7.74B |
|---|---|
| Revenue Growth (YoY) | +26.60% |
| Gross Margin | +74.29% |
| Operating Margin | +30.39% |
| Profit Margin | +20.13% |
| ROE | +14.91% |
| Debt / Equity | 20.66 |
| Current Ratio | 1.38 |
| Total Cash | $2.36B |
| Total Debt | $2.24B |
| Free Cash Flow | $1.83B |
Source: Nexqual, July 25, 2026 at 02:25 UTC.
Financial Health Score (UCBJY)
Nexqual rates UCBJY's overall financial health "Strong" across five dimensions, as of July 25, 2026 at 02:25 UTC.
| Growth | Strong — Revenue +26% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 74%, operating 30% |
| Balance Sheet | Strong — $2.36B cash vs $2.24B debt, net cash position |
| Cash Flow | Strong — FCF $1.83B, 24% margin |
| Efficiency | Mixed — ROE 15%, ROA 7.0% |
Ownership (UCBJY)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.01% |
| Shares Outstanding | 380.72M |
| Float | 239.72M |
Source: Nexqual, July 25, 2026 at 02:25 UTC.
Leadership (UCBJY)
UCBJY is led by Jean-Christophe Tellier (age 66), CEO & Executive Director, per Nexqual as of July 25, 2026 at 02:25 UTC.
| CEO & Executive Director | Jean-Christophe Tellier (age 66) |
|---|---|
| Executive VP & CFO | Sandrine Dufour (age 59) |
| Executive VP & Chief Scientific Officer | Alistair Henry (age 58) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MKKGY | Merck KGaA | USD 31.88 | ▲ 2.02% |
| SAUHY | Straumann Holding AG | USD 11.64 | ▼ 1.61% |
| CSLLY | CSL Ltd. | USD 20 | ▼ 3.85% |
| FSNUY | Fresenius SE & Co. KGaA | USD 12.48 | ▲ 0.16% |
| GNMSF | Genmab A/S | USD 274.5 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 02:25 UTC. This page is informational and not investment advice.